An Influenza Resistance Information Study (IRIS)

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: April 15, 2009
Last updated: April 2, 2016
Last verified: April 2016
This study will assist in the early detection of influenza resistant to antivirals, and will monitor the clinical outcome of patients infected with influenza according to subtype and susceptibility. Patients clinically diagnosed with influenza will undergo a rapid diagnostic test, and viral sampling at baseline and on days 3 and 6. Patients will be clinically managed according to local guidelines (no treatment, or treatment with neuraminidase inhibitors or other appropriate therapies).

Condition Intervention
Procedure: Virology testing

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: An Open Label Study to Examine Natural Prevalence and/or Emergence of Resistance to Antivirals Among Influenza Virus Isolates, and of the Clinical Outcome of Patients With Influenza: Influenza Resistance Information Study (IRIS)

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Natural prevalence and/or emergence of resistance to antivirals among influenza virus isolates [ Time Frame: Baseline, and days 3 and 6 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Genotypic and phenotypic characteristics of circulating viral strains [ Time Frame: Baseline, and days 3 and 6 ] [ Designated as safety issue: No ]
  • Signs and symptoms of patients infected with different subtypes of seasonal influenza [ Time Frame: Baseline, and days 3 and 6 ] [ Designated as safety issue: No ]
  • Adverse events [ Time Frame: Days 3 and 6 ] [ Designated as safety issue: No ]

Enrollment: 4184
Study Start Date: January 2009
Study Completion Date: November 2015
Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1 Procedure: Virology testing
Virology testing (nasal/throat swabs) will be taken at baseline, and on days 3 and 6


Ages Eligible for Study:   1 Year and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients presenting with clinical signs and symptoms of influenza during the local influenza season

Inclusion Criteria:

  • patients>=1 year of age;
  • symptoms suggestive of influenza-like illness including, but not limited to, fever, cough or coryza.

Exclusion Criteria:

  • allergy to any potential influenza therapy;
  • more than one patient from same household or residential/care home.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00884117

United States, Illinois
Chicago, Illinois, United States, 60655
Australia, New South Wales
Westmead, New South Wales, Australia, 2145
Bron, France, 69677
Berlin, Germany, 14052
Hong Kong
Shatin, Hong Kong
Rotterdam, Netherlands, 3000 CA
Sandnes, Norway, 4313
Krakow, Poland, 31-159
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Hoffmann-La Roche Identifier: NCT00884117     History of Changes
Other Study ID Numbers: NV20237  2008-006149-24 
Study First Received: April 15, 2009
Last Updated: April 2, 2016
Health Authority: France:Agence francaise de securite sanitaire des produits de sante

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Respiratory Tract Diseases
Respiratory Tract Infections
Virus Diseases processed this record on May 26, 2016